COMMUNIQUÉS West-GlobeNewswire

Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results

07/11/2017 - 13:00

BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial [...]

Aclaris Therapeutics Reports Third Quarter 2017 Financial Results

07/11/2017 - 13:00

Management to Host Conference Call at 8:00 AM ET today

Targovax ASA: Notice of Extraordinary General Meeting

07/11/2017 - 11:39

An Extraordinary General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 30 November 2017 at 13:00 CET. Please find the notice including agenda for the Extraordinary General Meeting and [...]

Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

07/11/2017 - 08:00

Top-line data from the study now expected in mid-2018 LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on [...]

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

07/11/2017 - 08:00

Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or [...]

Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation

07/11/2017 - 07:30

ORION CORPORATION PRESS RELEASE 7 NOVEMBER 2017 at 8.30 EET Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation Professor Heikki Joensuu, M.D., Ph.D., has [...]

Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage

07/11/2017 - 07:15

Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx ® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced mobility and irreversible joint [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

07/11/2017 - 07:10

REGULATED INFORMATION GHENT, Belgium, 7 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

07/11/2017 - 07:05

REGULATED INFORMATION GHENT, Belgium, 7 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

CORRECTION OF PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

07/11/2017 - 07:00

REGULATED INFORMATION GHENT, Belgium, 7 November 2017 - Ablynx [Euronext Brussels and Nasdaq: ABLX] announced on 3 November 2017, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication [...]

Todd Bazemore Steps Down from Role as Chief Operating Officer of Santhera's US Subsidiary

06/11/2017 - 20:36

Liestal, Switzerland, November 6, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that Todd Bazemore resigns his role as Chief Operating Officer of Santhera Pharmaceuticals (USA) Inc. and member of executive [...]

VALNEVA : Déclaration d'actions et de droits de vote octobre 2017

06/11/2017 - 18:00

VALNEVA Déclaration d'actions et de droits de vote - OCTOBRE 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon - Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]

Essilor : Nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2017

06/11/2017 - 18:00

Nombre total de droits de vote et d'actions composant le capital social au 31 octobre 2017 (Article L.233-8 II du Code de Commerce et les articles 221-1 et 223-16 du Règlement Général de l'AMF) Charenton-le-Pont, France [...]

Essilor: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2017

06/11/2017 - 18:00

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2017 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]

Le MABp1 de XBiotech fera l'objet d'une présentation orale lors des séances scientifiques de l'American Heart Association

06/11/2017 - 17:28

Présentation pour discuter des nouveaux résultats sur MABp1 dans la prévention de la thrombose coronaire AUSTIN, Texas, le 3 novembre 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui que la [...]

Ossur Hf : Transactions in relation to share buyback program

06/11/2017 - 17:00

Announcement from Össur hf. No. 80/2017 Reykjavík, 6 November 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]

Acarix AB to seek new CEO

06/11/2017 - 14:40

Press release Malmö, November 6, 2017 Acarix AB to seek new CEO Acarix AB (publ) ("Acarix") announced today that CEO Søren Rysholt Christiansen has resigned on 6 Nov. 2017, with the effect to leave the company at the [...]

Adaptimmune marks Official Opening of U.K. Headquarters

06/11/2017 - 14:15

Flagship Facility is new Base for U.K. Research and Development Operations PHILADELPHIA and OXFORD, U.K., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat [...]

Novo Nordisk A/S - Share repurchase programme

06/11/2017 - 13:31

Bagsværd, Denmark, 6 November 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]